Imprimis Pharmaceuticals (NASDAQ: IMMY) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Imprimis Pharmaceuticals to related businesses based on the strength of its earnings, analyst recommendations, institutional ownership, risk, profitability, valuation and dividends.


This table compares Imprimis Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Imprimis Pharmaceuticals -60.71% -264.98% -57.30%
Imprimis Pharmaceuticals Competitors -5,346.43% -217.96% -40.67%

Risk and Volatility

Imprimis Pharmaceuticals has a beta of -0.37, indicating that its share price is 137% less volatile than the S&P 500. Comparatively, Imprimis Pharmaceuticals’ rivals have a beta of 2.68, indicating that their average share price is 168% more volatile than the S&P 500.

Institutional & Insider Ownership

12.6% of Imprimis Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 12.6% of Imprimis Pharmaceuticals shares are owned by insiders. Comparatively, 17.3% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Imprimis Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Imprimis Pharmaceuticals $19.94 million -$19.08 million -1.78
Imprimis Pharmaceuticals Competitors $284.49 million $34.10 million 70.57

Imprimis Pharmaceuticals’ rivals have higher revenue and earnings than Imprimis Pharmaceuticals. Imprimis Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Imprimis Pharmaceuticals and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Imprimis Pharmaceuticals 0 0 1 0 3.00
Imprimis Pharmaceuticals Competitors 882 3259 11753 235 2.70

Imprimis Pharmaceuticals currently has a consensus price target of $5.00, indicating a potential upside of 204.88%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.49%. Given Imprimis Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Imprimis Pharmaceuticals is more favorable than its rivals.


Imprimis Pharmaceuticals rivals beat Imprimis Pharmaceuticals on 9 of the 13 factors compared.

Imprimis Pharmaceuticals Company Profile

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.